The American Society of Hematology (ASH) has published new clinical practice guidelines aimed at improving the early, timely, and accurate diagnosis of light chain (AL) amyloidosis.1The guidelines were published January 28, 2026, in Blood Advances and outline best practices to support clinicians in recognizing and diagnosing AL amyloidosis, a disease frequently missed or diagnosed late due to its heterogeneous presentation.1“These guidelines will be a valuable resource not only for hematologists, but for clinicians across other specialties who care for patients with AL amyloidosis,” said Robert Negrin, MD, ASH President, in a statement. “Because this is a rare and often underrecognized disorder, these recommendations are particularly important for coordinating care and increasing awareness.”AL amyloidosis is typically a multisystem disease, with amyloid deposits affecting multiple organs. The heart and kidneys are most commonly involved, potentially resulting in cardiomyopathy, renal failure, and pleural or pericardial effusions. For each recommendation, the Evidence-Based Practice and Impact Center at the University of Kansas Health System conducted systematic evidence reviews and developed GRADE Evidence-to-Decision frameworks to guide recommendations.1The guidelines recommend the use of blood and urine testing, including serum immunofixation, urine immunofixation, and serum free light chain assays, when clinical suspicion for AL amyloidosis exists. “These guidelines will help clinicians across disciplines think of this disease in the right scenarios and provide them with the necessary tools to obtain a clear, accurate diagnosis as quickly as possible.”1Currently, the panel is developing follow-up guidelines focused on the treatment of AL amyloidosis.1